Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.55 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.52 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.49 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.44 |
| ▸ | DGAT2 | Q96PD7 | 3/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | GRK6 | P43250 | 1/20 | 0.42 |
| ▸ | TEK | Q02763 | 1/20 | 0.42 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6452381 | 0.83 | SMN1; SMN2 (0.52) | NR1H2NR1H3DCUN1D1CYP19A1NPC1 | |
| SCHEMBL6449912 | 0.83 | GRK6 (0.46) | NR1H2NR1H3RPS6KA3GRK6TEK | |
| SCHEMBL6452904 | 0.83 | GRK6 (0.44) | GRK6TEKNPC1MAPT | |
| SCHEMBL6454834 | 0.82 | GRK6 (0.45) | CYP19A1GRK6TEKNPC1RAB9A | |
| SCHEMBL6448731 | 0.79 | NR1H2 (0.56) | NR1H2NR1H3ADORA2AADORA1DCUN1D1 | |
| SCHEMBL6449759 | 0.79 | MAPT (0.52) | GRK6NPC1RAB9ACYP1A2CYP3A4 | |
| SCHEMBL6453081 | 0.78 | SMN1; SMN2 (0.44) | NR1H2NR1H3RPS6KA3NPC1RAB9A | |
| SCHEMBL6450295 | 0.77 | KDM4E (0.41) | DCUN1D1SLC22A12MAPT | |
| SCHEMBL17279794 | 0.76 | NR1H2 (0.86) | NR1H2NR1H3ADORA2AADORA1DCUN1D1 | |
| SCHEMBL6453811 | 0.76 | NR1H2 (0.49) | NR1H2NR1H3NPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| WO-2004110351-A2 | HETEROCYCLIC COMPOUNDS FOR TREATING HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | NR1H2 34/4885NR1H3 24/4885ADORA2A 1442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.